This Lonquex market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to the aging population, increased awareness of neutropenia, a rise in immunocompromised individuals, the rapid growth of oncology drugs, and the growing prevalence of autoimmune diseases.
The projected growth for the forecast period can be attributed to the shift toward patient-centric healthcare, a greater focus on preventive healthcare, the development of more accurate diagnostic tools, an increase in hematological disorders, and an expanding focus on rare diseases. Key trends during this period include advancements in biotechnology, personalized cancer therapies, innovations in biologics, progress in genetic research and diagnostics, and advancements in combination therapies.
The growing incidence of cancer is expected to drive the expansion of the lonquex market in the coming years. Cancer incidence refers to the number of new cancer cases diagnosed within a specific population over a defined period, usually expressed per 100,000 individuals annually. The increase in cancer cases can be attributed to factors such as an aging population, lifestyle changes (including higher tobacco and alcohol consumption), environmental exposure to carcinogens, genetic factors, and improved diagnostic methods. Lonquex (lipegfilgrastim) helps reduce the risk of infection in cancer patients by boosting the production of white blood cells, thus mitigating the effects of chemotherapy-induced neutropenia. For example, the American Cancer Society’s 2023 Facts and Figures report indicates that over 1.9 million new cancer cases were diagnosed in the U.S. in 2023, with projections of more than 2 million cases in 2024. Therefore, the rising cancer rates are fueling the growth of the lonquex market.
The growth of biosimilars is anticipated to drive the lonquex market forward. Biosimilars are biologic medical products that closely resemble already approved reference biologic drugs, with no significant differences in safety, efficacy, or potency. The increase in biosimilars is attributed to efforts to contain healthcare costs, the expiration of patents for biologic drugs, the rising prevalence of chronic diseases, and growing acceptance of biosimilars among healthcare providers and patients. Lonquex (lipegfilgrastim) functions as a biosimilar by mimicking the natural activity of granulocyte colony-stimulating factor (G-CSF), stimulating the production and release of neutrophils from the bone marrow, thereby reducing infection risk in chemotherapy patients. For instance, as of January 2022, the U.S. had 33 FDA-approved biosimilars, 21 of which were commercially available, according to Cardinal Health Inc. This expansion in biosimilars is contributing to the growth of the lonquex market.
In August 2024, Lotus Pharmaceutical Co. Ltd., a pharmaceutical company based in Taiwan, acquired Teva Pharma (Thailand) Co. Ltd., a move aimed at expanding its presence in Southeast Asia. The acquisition will enhance Lotus Pharmaceuticals' oncology and women’s health product offerings, while also granting access to Teva’s ophthalmic and respiratory portfolios. This strategic acquisition will strengthen Lotus' presence in both the hospital and pharmacy sectors in Thailand. Teva Pharma (Thailand) Co. Ltd. is a Thailand-based company that specializes in providing lonquex.
The key company operating in the lonquex market is Teva Pharmaceutical Industries Ltd.
North America was the largest region in the lonquex market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lonquex report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lonquex market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Lonquex is a medication containing lipegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF) that stimulates the production of white blood cells. It is primarily prescribed to treat severe neutropenia, a condition where there is a low level of neutrophils, which are crucial for fighting infections. Neutropenia commonly occurs in patients undergoing chemotherapy, as chemotherapy can impair the bone marrow’s ability to produce white blood cells.
The main formulations of lonquex are injectable solutions, which come in pre-filled syringes or auto-injectors. These injectable formulations allow for direct delivery of the medication into the body, ensuring rapid and effective results, particularly in hospital settings for treating conditions such as neutropenia. Indications for Lonquex include the prevention of chemotherapy-induced neutropenia, treatment of neutropenia in hematological malignancies, and supportive care during chemotherapy. The patient demographics include adults, geriatric patients, and pediatric patients. Distribution occurs through direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies, with end users including hospitals, oncology clinics, dermatology clinics, and research institutions.
The lonquex market research report is one of a series of new reports that provides lonquex market statistics, including the lonquex industry global market size, regional shares, competitors with the lonquex market share, detailed lonquex market segments, market trends, and opportunities, and any further data you may need to thrive in the lonquex industry. This lonquex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The lonquex market consists of sales of CAR T-cell therapy kits, granulocyte colony-stimulating factor (G-CSF) drugs, and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to the aging population, increased awareness of neutropenia, a rise in immunocompromised individuals, the rapid growth of oncology drugs, and the growing prevalence of autoimmune diseases.
The projected growth for the forecast period can be attributed to the shift toward patient-centric healthcare, a greater focus on preventive healthcare, the development of more accurate diagnostic tools, an increase in hematological disorders, and an expanding focus on rare diseases. Key trends during this period include advancements in biotechnology, personalized cancer therapies, innovations in biologics, progress in genetic research and diagnostics, and advancements in combination therapies.
The growing incidence of cancer is expected to drive the expansion of the lonquex market in the coming years. Cancer incidence refers to the number of new cancer cases diagnosed within a specific population over a defined period, usually expressed per 100,000 individuals annually. The increase in cancer cases can be attributed to factors such as an aging population, lifestyle changes (including higher tobacco and alcohol consumption), environmental exposure to carcinogens, genetic factors, and improved diagnostic methods. Lonquex (lipegfilgrastim) helps reduce the risk of infection in cancer patients by boosting the production of white blood cells, thus mitigating the effects of chemotherapy-induced neutropenia. For example, the American Cancer Society’s 2023 Facts and Figures report indicates that over 1.9 million new cancer cases were diagnosed in the U.S. in 2023, with projections of more than 2 million cases in 2024. Therefore, the rising cancer rates are fueling the growth of the lonquex market.
The growth of biosimilars is anticipated to drive the lonquex market forward. Biosimilars are biologic medical products that closely resemble already approved reference biologic drugs, with no significant differences in safety, efficacy, or potency. The increase in biosimilars is attributed to efforts to contain healthcare costs, the expiration of patents for biologic drugs, the rising prevalence of chronic diseases, and growing acceptance of biosimilars among healthcare providers and patients. Lonquex (lipegfilgrastim) functions as a biosimilar by mimicking the natural activity of granulocyte colony-stimulating factor (G-CSF), stimulating the production and release of neutrophils from the bone marrow, thereby reducing infection risk in chemotherapy patients. For instance, as of January 2022, the U.S. had 33 FDA-approved biosimilars, 21 of which were commercially available, according to Cardinal Health Inc. This expansion in biosimilars is contributing to the growth of the lonquex market.
In August 2024, Lotus Pharmaceutical Co. Ltd., a pharmaceutical company based in Taiwan, acquired Teva Pharma (Thailand) Co. Ltd., a move aimed at expanding its presence in Southeast Asia. The acquisition will enhance Lotus Pharmaceuticals' oncology and women’s health product offerings, while also granting access to Teva’s ophthalmic and respiratory portfolios. This strategic acquisition will strengthen Lotus' presence in both the hospital and pharmacy sectors in Thailand. Teva Pharma (Thailand) Co. Ltd. is a Thailand-based company that specializes in providing lonquex.
The key company operating in the lonquex market is Teva Pharmaceutical Industries Ltd.
North America was the largest region in the lonquex market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lonquex report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lonquex market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Lonquex is a medication containing lipegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF) that stimulates the production of white blood cells. It is primarily prescribed to treat severe neutropenia, a condition where there is a low level of neutrophils, which are crucial for fighting infections. Neutropenia commonly occurs in patients undergoing chemotherapy, as chemotherapy can impair the bone marrow’s ability to produce white blood cells.
The main formulations of lonquex are injectable solutions, which come in pre-filled syringes or auto-injectors. These injectable formulations allow for direct delivery of the medication into the body, ensuring rapid and effective results, particularly in hospital settings for treating conditions such as neutropenia. Indications for Lonquex include the prevention of chemotherapy-induced neutropenia, treatment of neutropenia in hematological malignancies, and supportive care during chemotherapy. The patient demographics include adults, geriatric patients, and pediatric patients. Distribution occurs through direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies, with end users including hospitals, oncology clinics, dermatology clinics, and research institutions.
The lonquex market research report is one of a series of new reports that provides lonquex market statistics, including the lonquex industry global market size, regional shares, competitors with the lonquex market share, detailed lonquex market segments, market trends, and opportunities, and any further data you may need to thrive in the lonquex industry. This lonquex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The lonquex market consists of sales of CAR T-cell therapy kits, granulocyte colony-stimulating factor (G-CSF) drugs, and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Lonquex Market Characteristics4. Lonquex Market Trends and Strategies5. Lonquex Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Lonquex Pricing Analysis & Forecasts30. Global Lonquex Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Lonquex Market32. Recent Developments in the Lonquex Market
3. Lonquex Market Biologic Drug Characteristics
6. Global Lonquex Growth Analysis and Strategic Analysis Framework
8. Lonquex Market Segmentation
9. Global Lonquex Epidemiology of Clinical Indications
10. Lonquex Market Regional and Country Analysis
11. Asia-Pacific Lonquex Market
12. China Lonquex Market
13. India Lonquex Market
14. Japan Lonquex Market
15. Australia Lonquex Market
16. South Korea Lonquex Market
17. Western Europe Lonquex Market
18. UK Lonquex Market
19. Germany Lonquex Market
20. France Lonquex Market
21. Eastern Europe Lonquex Market
22. North America Lonquex Market
23. USA Lonquex Market
24. Canada Lonquex Market
25. South America Lonquex Market
26. Middle East Lonquex Market
27. Africa Lonquex Market
28. Lonquex Market Competitive Landscape and Company Profiles
29. Global Lonquex Market Pipeline Analysis
33. Lonquex Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Lonquex Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on lonquex market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for lonquex? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lonquex market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Prevention of Chemotherapy-Induced Neutropenia; Treatment of Neutropenia in Hematological Malignancies; Supportive Care for Chemotherapy2) by Formulation: Injectable Formulation (Solution For Injection); Pre-Filled Syringes or Auto-Injectors
3) by Patient Demographics: Adult Patients; Geriatric Patients; Pediatric Patients
4) by Distribution Channel: Direct Sales; Wholesalers and Distributors; Retail Pharmacies; Online Pharmacies
5) by End User: Hospitals; Oncology Clinics; Dermatology Clinics; Research Institutions
Key Companies Mentioned: Teva Pharmaceutical Industries Ltd
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Teva Pharmaceutical Industries Ltd
